Evidence map›Paper›PMID 32857187›Full record

ArticlePsychopharmacology2020

Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats.

Udita Datta, Leslie K Kelley, Jason W Middleton, Nicholas W Gilpin

Open access · greenAbstract read
In one paragraph

Article in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Short Tandem Repeat Variation in theFrontiers in genetics · 2022
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Udita DattaDepartment of Physiology, Louisiana State University Health Science Center, Room 7205 1901 Perdido Street, New Orleans, LA, 70112, USA.
Leslie K KelleyDepartment of Physiology, Louisiana State University Health Science Center, Room 7205 1901 Perdido Street, New Orleans, LA, 70112, USA.
Jason W MiddletonDepartment of Cell Biology & Anatomy, Louisiana State University Health Science Center, New Orleans, LA, 70112, USA.
Nicholas W GilpinDepartment of Physiology, Louisiana State University Health Science Center, Room 7205 1901 Perdido Street, New Orleans, LA, 70112, USA. ngilpi@lsuhsc.edu.
Louisiana State University Health Sciences Center New Orleans · USJackson Laboratory · US

Funding

Role of Neuropeptides in Stress-Induced Escalation of Alcohol DrinkingR01AA023305 · NIAAA · LSU HEALTH SCIENCES CENTER · PI GILPIN, NICHOLAS WARREN · 2014 to 2024
$3.7M
Targeting Melanocortin-4 Receptors to Reduce Pain in U.S. VeteransI01BX003451 · VA · SOUTHEAST LOUISIANA VETERANS HEALTH CARE · PI GILPIN, NICHOLAS WARREN · 2017 to 2025
–
BLRD VA I01 BX003451NIAAA NIH HHS R01 AA023305NIH HHS AA023305
6 · The paper itself

Abstract

Opioid drugs are a first-line treatment for severe acute pain and other chronic pain conditions, but long-term opioid drug use produces opioid-induced hyperalgesia (OIH). Co-administration of cannabinoids with opioid receptor agonists produce anti-nociceptive synergy, but cannabinoid receptor agonists may also produce undesirable side effects. Therefore, positive allosteric modulators (PAM) of cannabinoid type-1 receptors (CB1R) may provide an option reducing pain and/or enhancing the anti-hyperalgesic effects of opioids without the side effects, tolerance, and dependence observed with the use of ligands that target the orthosteric binding sites. This study tested GAT211, a PAM of cannabinoid type-1 receptors (CB1R), for its ability to enhance the anti-hyperalgesic effects of the mu-opioid receptor (MOR) agonist DAMGO in rats treated chronically with morphine (or saline) and tested during withdrawal. We tested the effects of intra-periaqueductal gray (PAG) injections of (1) DAMGO, (2) GAT211, or (3) DAMGO + GAT211 on thermal nociception in chronic morphine-treated rats that were hyperalgesic and also in saline-treated control rats. We used slice electrophysiology to test the effects of DAMGO/GAT211 bath application on synaptic transmission in the vlPAG. Intra-PAG DAMGO infusions dose-dependently reversed chronic morphine-induced hyperalgesia, but intra-PAG GAT211 did not alter nociception at the doses we tested. When co-administered into the PAG, GAT211 antagonized the anti-nociceptive effects of DAMGO in morphine-withdrawn rats. DAMGO suppressed synaptic inhibition in the vlPAG of brain slices taken from saline- and morphine-treated rats, and GAT211 attenuated DAMGO-induced suppression of synaptic inhibition in vlPAG neurons via actions at CB1R. These findings show that positive allosteric modulation of CB1R antagonizes the behavioral and cellular effects of a MOR agonist in the PAG of rats.

Indexed as

Allosteric RegulationAnalgesics, OpioidAnimalsCannabinoid Receptor AgonistsEnkephalin, Ala(2)-MePhe(4)-Gly(5)-HyperalgesiaMaleMicroinjectionsMorphineNociceptionPeriaqueductal GrayRatsRats, WistarReceptor, Cannabinoid, CB1Receptors, Opioid, muSubstance Withdrawal SyndromeAnalgesics, OpioidCannabinoid Receptor AgonistsEnkephalin, Ala(2)-MePhe(4)-Gly(5)-MorphineReceptor, Cannabinoid, CB1Receptors, Opioid, muDose-responseHyperalgesiaMorphineOpiatesOpioidsPAGPainPositive allosteric modulators

Identifiers

PMID32857187
PMCPMC7687722
OpenAlexW3082276918

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.